Product Services
Signaling pathway
-
-
-
Neurodegeneration—A Common Pathway Across Multiple Diseases (0)
-
The AGE–RAGE signaling pathway in diabetic complications (0)
-
PD-L1 Expression and the PD-1 Checkpoint Pathway in Cancer (0)
-
Epithelial Cell Signaling in Helicobacter pylori Infection (0)
-
Glioma-associated Kaposi’s sarcoma-associated herpesvirus infection (0)
Contact Us
Address: 14th Floor, Building A, Wuhan Guoying Seed Industry Building, No. 666, Shendun Fourth Road, Jiangxia District, Wuhan, Hubei Province
Email: pinuofei2017@163.com
TEL: 15392937510
Article Number: PL0436
Delivery time: 现货
Price: 50 μL/960; 100 μL/1600; 200 μL/2560
Category:
Target： FGA
Application： WB, IHC, IF, ELISA
Reactivity ： Human,Mouse,Rat
MW(CalcμLated) ： 95 kD
MW(Observed) ： 110 kD
Host Species： Rabbit
Isotype ： IgG, Kappa
隐藏域元素占位
Detailed Information
Recommended dilution ratio ： IHC 1:500-1:2000; WB 1:2000-1:10000; IF 1:200-1:1000; ELISA 1:5000-1:20000;
Compose ： PBS, 50% glycerol, 0.05% Proclin 300, 0.05% BSA
Purification process ： Protein A
Storage ： -15°C to -25°C/1 year(Do not lower than -25°C
Clonality ： Monoclonal
Clone Number ： PT1326R
Antigen & Target Information
Specificity ： Endogenous
Gene name ： FGA
Protein Name ： Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain]
Background：
This gene encodes the alpha subunit of the coagulation factor fibrinogen, which is a component of the blood clot. Following vascular injury, the encoded preproprotein is proteolytically processed by thrombin during the conversion of fibrinogen to fibrin. Mutations in this gene lead to several disorders, including dysfibrinogenemia, hypofibrinogenemia, afibrinogenemia and renal amyloidosis. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that undergoes proteolytic processing. [provided by RefSeq, Jan 2016],
Cell localization ： Disease: Defects in FGA are a cause of amyloidois type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.,Disease: Defects in FGA are a cause of congenital afibrinogenemia [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. The majority of cases of afibrinogenemia are due to truncating mutations.,Disease: Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.,Domain: A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.,Function: Fibrinogen has a double Function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.,online information: Fibrinogen entry,online information: The Singapore human mutation and polymorphism database,PTM: About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.,PTM: Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.,PTM: Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.,PTM: The alpha chain is not glycosylated.,similarity: Contains 1 fibrinogen C-terminal domain.,subunit: Heterohexamer; disulfide linked. Contains 2 sets of 3 non-identical chains (alpha, beta and gamma). The 2 heterotrimers are in head to head conformation with the N-termini in a small central domain.,
Recommended
Relevant Literature
We remain open to communication and look forward to supporting you.
Centered on our primary and secondary antibody products, we have established a strong foothold in the specialized antibody reagent market. Leveraging our independently developed core technology platform and a dedicated R&D and manufacturing team, we provide high‑reliability biological reagents and end‑to‑end technical solutions to universities, research institutes, biopharmaceutical companies, and other customers worldwide.
Support Services. Since its inception, Pinofibio has remained committed to a development philosophy centered on research needs. Through a robust R&D system, stringent quality control, and responsive, efficient service, the company is dedicated to building an antibody product portfolio that spans multiple species and targets, helping researchers overcome technical challenges and driving innovation in the biopharmaceutical industry.
Wuhan Pinofibio Biotechnology Co., Ltd.
Address: 14th Floor, Building A, Wuhan Guoying Seed Industry Building, No. 666, Shendun Fourth Road, Jiangxia District, Wuhan, Hubei Province
Email: pinuofei2017@163.com
TEL: 15392937510
Xiaohongshu
Experimental Services
Official Account
Antibody Services
微信客服